CA15-3

BriaCell 2023 SABCS Posters Confirm Activation of Cancer-Fighting Immune Cells and Identify Potential Predictors of Clinical Benefit

Retrieved on: 
Wednesday, December 6, 2023
Patient, Associate, Immunotherapy, Survival, CEA, CD8, Immune system, Breast cancer, BCT, Antibody, Clinical Radiology, Therapy, Cancer, University, Neoplasm, Lymphocyte, Poster, TSX, Cell, CA15-3, Vaccine

Today’s posters highlight the activation of cancer fighting immune cells by the Bria-IMT™ combination regimen that was identified using leading-edge technologies.

Key Points: 
  • Today’s posters highlight the activation of cancer fighting immune cells by the Bria-IMT™ combination regimen that was identified using leading-edge technologies.
  • “We were able to see that the Bria-IMT™ combination regimen treatment can activate cancer-fighting T cells to infiltrate some breast cancer tumors.
  • This indicates activation of these cells and their invasion into the tumors potentially leading to destruction of cancer cells.
  • We observed favorable changes in tumor markers (CEA and CA15-3), Circulating Tumor Cells, and Cancer Associated Macrophage Like cells suggesting activation of tumor fighting cells.